At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VERA Vera Therapeutics, Inc.
Trading 06-02 12:57:07 EDT
32.09
-1.85
-5.45%
High35.21Low31.55Vol793.89K
Open33.99D1 Closing33.94Amplitude10.78%
Mkt Cap2.30BTradable Cap1.61BTotal Shares71.71M
T/O25.84MT/O Rate1.58%Tradable Shares50.20M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Vera Therapeutics Aligns With FDA on Earlier Atacicept Analysis to Support Potential Full Approval
MT Newswires Live  ·  25 minutes ago
Vera Therapeutics Aligns With FDA on Earlier Atacicept Analysis to Support Potential Full Approval
Vera Therapeutics announces alignment with FDA on earlier ORIGIN 3 eGFR analysis
TIPRANKS  ·  30 minutes ago
Vera Therapeutics announces alignment with FDA on earlier ORIGIN 3 eGFR analysis
BUZZ-U.S. STOCKS ON THE MOVE-Dollar General, Vera, Amtech Systems
Reuters  ·  06-02 21:04
BUZZ-U.S. STOCKS ON THE MOVE-Dollar General, Vera, Amtech Systems
Vera Therapeutics: Buy Rating Reiterated as Atacicept’s Regulatory Path Advances; $90 Price Target Maintained
TIPRANKS  ·  06-02 20:55
Vera Therapeutics: Buy Rating Reiterated as Atacicept’s Regulatory Path Advances; $90 Price Target Maintained
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA), Vera Therapeutics (VERA) and Regeneron (REGN)
TIPRANKS  ·  06-02 20:00
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA), Vera Therapeutics (VERA) and Regeneron (REGN)
Vera Therapeutics Advances Atacicept Approval Path in IgA Nephropathy
TIPRANKS  ·  06-02 19:37
Vera Therapeutics Advances Atacicept Approval Path in IgA Nephropathy
BUZZ-Vera rises as FDA agrees to review late-stage kidney drug data for full approval
Reuters  ·  06-02 19:36
BUZZ-Vera rises as FDA agrees to review late-stage kidney drug data for full approval
Vera Therapeutics pulls forward ORIGIN phase 3 eGFR analysis of atacicept in IgA nephropathy to Q3 2026
Reuters  ·  06-02 19:03
Vera Therapeutics pulls forward ORIGIN phase 3 eGFR analysis of atacicept in IgA nephropathy to Q3 2026
Vera Therapeutics, - Revised Origin 3 Egfr Analysis Planned for Q3 2026
THOMSON REUTERS  ·  06-02 19:00
Vera Therapeutics, - Revised Origin 3 Egfr Analysis Planned for Q3 2026
Vera Therapeutics Announces Alignment With U.S. FDA on Earlier Origin Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults With Iga Nephropathy
THOMSON REUTERS  ·  06-02 19:00
Vera Therapeutics Announces Alignment With U.S. FDA on Earlier Origin Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults With Iga Nephropathy
Vera Therapeutics, - Pdufa Date Set for July 7, 2026 for Atacicept in Igan
THOMSON REUTERS  ·  06-02 19:00
Vera Therapeutics, - Pdufa Date Set for July 7, 2026 for Atacicept in Igan
Vera Therapeutics, - Plans to Submit Sbla in Q4 2026 for Potential Full Approval in 2027
THOMSON REUTERS  ·  06-02 19:00
Vera Therapeutics, - Plans to Submit Sbla in Q4 2026 for Potential Full Approval in 2027
Vera Therapeutics shareholders elect Class II directors at annual meeting
Reuters  ·  05-27
Vera Therapeutics shareholders elect Class II directors at annual meeting
Analysts’ Top Healthcare Picks: Concentra Group Holdings Parent, Inc. (CON), Vera Therapeutics (VERA)
TIPRANKS  ·  05-23
Analysts’ Top Healthcare Picks: Concentra Group Holdings Parent, Inc. (CON), Vera Therapeutics (VERA)
Analysts Are Bullish on These Healthcare Stocks: Inovio Pharmaceuticals (INO), Vera Therapeutics (VERA)
TIPRANKS  ·  05-22
Analysts Are Bullish on These Healthcare Stocks: Inovio Pharmaceuticals (INO), Vera Therapeutics (VERA)
Vera Therapeutics (VERA) Is Down 11.6% After Wider Q1 Loss Highlights Rising Cost Burden
Simply Wall St.  ·  05-22
Vera Therapeutics (VERA) Is Down 11.6% After Wider Q1 Loss Highlights Rising Cost Burden
Vera Therapeutics Is Maintained at Outperform by Evercore ISI Group
Dow Jones  ·  05-16
Vera Therapeutics Is Maintained at Outperform by Evercore ISI Group
Vera Therapeutics (VERA) Receives a Buy from Evercore ISI
TIPRANKS  ·  05-15
Vera Therapeutics (VERA) Receives a Buy from Evercore ISI
Vera Therapeutics CEO Marshall Fordyce disposes 18,500 shares for $834,058
Reuters  ·  05-14
Vera Therapeutics CEO Marshall Fordyce disposes 18,500 shares for $834,058
Vera Therapeutics grants inducement equity awards to 10 new hires, sets options at $35.51
Reuters  ·  05-09
Vera Therapeutics grants inducement equity awards to 10 new hires, sets options at $35.51

Introduction

Company Name.
Vera Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Issue price:
--